Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive Disorder

• Author(s): Santos, M. ; Carvalho, S. ; Lima, L. ; Mota-Pereira, J. ; Pimentel, P. ; Correia, D. ; Maia, D. ; Gomes, S. ; Cruz, A. ; Medeiros, R.
• Date: 2022
• Persistent ID: http://hdl.handle.net/10400.22/21698
• Origin: Repositório Científico do Instituto Politécnico do Porto
• Document Type: Journal article
• Language: English
• Contributor(s): REPOSITÓRIO P.PORTO

Description

Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. Several authors have been pointing out the role of the BDNF-TrkB signaling pathway, including the downstream kinases Akt and ERK, and the mTOR pathway in neuroplasticity [1-3]. Furthermore, the prediction of AD response phenotypes of depressed patients treated with AD drugs remains a challenge for clinicians. Although previous studies have suggested that genetic variants may play a key role in the mechanism of Treatment Resistance Depression and Relapse, attempts to identify risk polymorphisms within genes with putative interest in AD response, had a limited success.